Pfizer Inc. $PFE Shares Sold by Anson Funds Management LP

Key Points

• Anson Funds Management LP decreased its stake in Pfizer Inc. by 25%, selling 30,000 shares, leaving them with 90,000 shares valued at approximately $2.28 million.
• Pfizer reported a 10.3% year-over-year increase in revenue, reaching $14.65 billion, and earnings per share of $0.78, surpassing analysts' expectations.
• The company declared a quarterly dividend of $0.43 per share, reflecting an annualized dividend yield of 6.7%.

Anson Funds Management LP reduced its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 25.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 90,000 shares of the biopharmaceutical company's stock after selling 30,000 shares during the quarter. Anson Funds Management LP's holdings in Pfizer were worth $2,281,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in PFE. Brighton Jones LLC grew its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares during the period. Capital Analysts LLC grew its holdings in shares of Pfizer by 16.1% during the 4th quarter. Capital Analysts LLC now owns 24,656 shares of the biopharmaceutical company's stock worth $654,000 after purchasing an additional 3,424 shares during the period. Coldstream Capital Management Inc. grew its holdings in shares of Pfizer by 110.1% during the 4th quarter. Coldstream Capital Management Inc. now owns 227,323 shares of the biopharmaceutical company's stock worth $6,031,000 after purchasing an additional 119,111 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Pfizer during the 4th quarter worth $34,536,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 2.8%

PFE traded down $0.73 during mid-day trading on Monday, hitting $25.15. 32,304,503 shares of the stock were exchanged, compared to its average volume of 44,473,524. The firm's fifty day moving average is $24.72 and its two-hundred day moving average is $24.39. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $142.99 billion, a PE ratio of 13.38, a PEG ratio of 0.92 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer's revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PFE. Jefferies Financial Group increased their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Wolfe Research increased their price target on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Berenberg Bank lowered their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Finally, Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.